Network meta-analysis of 3 RCTs (2293 patients) with muscle-invasive bladder cancer: versus gemcitabine-cisplatin, perioperative enfortumab vedotin-pembrolizumab (OS HR 0.65) and GC plus durvalumab (HR 0.75) were associated with improved overall survival; indirect estimates only.
Meta-analysisn = 2,293
Maiorano et al. Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials